Neuropace Stock Current Valuation
| NPCE Stock | USD 13.53 0.14 1.05% |
Valuation analysis of Neuropace helps investors to measure Neuropace's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value is expected to grow to about 433.9 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (13.18). Fundamental drivers impacting Neuropace's valuation include:
Price Book 18.4445 | Enterprise Value 385.5 M | Enterprise Value Ebitda (16.94) | Price Sales 5.8491 | Enterprise Value Revenue 5.9139 |
Overvalued
Today
Please note that Neuropace's price fluctuation is slightly risky at this time. Calculation of the real value of Neuropace is based on 3 months time horizon. Increasing Neuropace's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Neuropace is useful when determining the fair value of the Neuropace stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Neuropace. Since Neuropace is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neuropace Stock. However, Neuropace's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 13.53 | Real 10.09 | Target 7.8 | Hype 13.53 | Naive 12.51 |
The real value of Neuropace Stock, also known as its intrinsic value, is the underlying worth of Neuropace Company, which is reflected in its stock price. It is based on Neuropace's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Neuropace's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Neuropace's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Neuropace helps investors to forecast how Neuropace stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neuropace more accurately as focusing exclusively on Neuropace's fundamentals will not take into account other important factors: Neuropace Company Current Valuation Analysis
Neuropace's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Neuropace Current Valuation | 385.48 M |
Most of Neuropace's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neuropace is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Neuropace Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Neuropace is extremely important. It helps to project a fair market value of Neuropace Stock properly, considering its historical fundamentals such as Current Valuation. Since Neuropace's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neuropace's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neuropace's interrelated accounts and indicators.
Click cells to compare fundamentals
Neuropace Current Valuation Historical Pattern
Today, most investors in Neuropace Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Neuropace's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Neuropace current valuation as a starting point in their analysis.
Neuropace Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Neuropace has a Current Valuation of 385.48 M. This is 97.32% lower than that of the Health Care Equipment & Supplies sector and 96.9% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.68% higher than that of the company.
Neuropace Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neuropace's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neuropace could also be used in its relative valuation, which is a method of valuing Neuropace by comparing valuation metrics of similar companies.Neuropace is currently under evaluation in current valuation category among related companies.
Neuropace Fundamentals
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 385.48 M | ||||
| Shares Outstanding | 28.72 M | ||||
| Shares Owned By Insiders | 3.90 % | ||||
| Shares Owned By Institutions | 77.92 % | ||||
| Number Of Shares Shorted | 97.14 K | ||||
| Price To Book | 18.44 X | ||||
| Price To Sales | 5.85 X | ||||
| Revenue | 65.42 M | ||||
| Gross Profit | 32.49 M | ||||
| EBITDA | (25.57 M) | ||||
| Net Income | (32.96 M) | ||||
| Cash And Equivalents | 92.41 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 72.39 M | ||||
| Debt To Equity | 1.08 % | ||||
| Current Ratio | 9.86 X | ||||
| Book Value Per Share | 0.74 X | ||||
| Cash Flow From Operations | (19.7 M) | ||||
| Short Ratio | 0.72 X | ||||
| Earnings Per Share | (1.27) X | ||||
| Target Price | 17.83 | ||||
| Number Of Employees | 171 | ||||
| Beta | 2.09 | ||||
| Market Capitalization | 384.56 M | ||||
| Total Asset | 107.65 M | ||||
| Retained Earnings | (503.81 M) | ||||
| Working Capital | 76.49 M | ||||
| Net Asset | 107.65 M |
About Neuropace Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neuropace's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuropace using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuropace based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Neuropace Piotroski F Score and Neuropace Altman Z Score analysis. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.Note that the Neuropace information on this page should be used as a complementary analysis to other Neuropace's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Neuropace's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 2.531 | Quarterly Revenue Growth 0.408 | Return On Assets (0.15) | Return On Equity (1.19) |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.